HEALTHTECH SECURITY

Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints

Medtronic plc | August 29, 2022 | Read time : 03:00 min

Medtronic Extravascular

Medtronic plc a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. Findings from the Extravascular Implantable Cardioverter Defibrillator Pivotal Study were presented as late-breaking science today at the European Society of Cardiology Congress 2022 in Barcelona and simultaneously published in The New England Journal of Medicine. Worldwide, the EV ICD system is investigational and not yet approved for sale or distribution.

The Medtronic EV ICD system is designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest while avoiding certain risks of traditional, transvenous ICDs because its lead (thin wire) is placed outside the heart and veins, under the breastbone (sternum) using a minimally invasive approach. Placing the lead in this location is designed to help avoid long-term complications that may be associated with leads in the heart and veins, such as vessel occlusion and risks for blood infections.

The lead is connected to a device that is implanted below the left armpit. Clinical trial participants received the same therapies provided by traditional ICDs, including defibrillation, anti-tachycardia pacing (ATP), and back-up pacing therapies with this single implanted device that is similar in size, shape, and longevity to traditional ICDs.

"We are very encouraged by the high defibrillation effectiveness and strong safety profile of the EV ICD system seen in the study, as we look to deliver less-invasive treatment options for patients at risk of sudden cardiac arrest. These results demonstrate the potential for this novel technology to be used as a safe, successful approach for patients with life-threatening arrhythmias."

Ian Crozier, MB, CHB, M.D., Christchurch Hospital, Christchurch, New Zealand, who presented the results at ESC Congress 2022

At six months, 25 major complications were observed in 23 of 316 patients who underwent an implant attempt (7.3%). Twenty-nine patients experienced inappropriate shocks (9.7%, average 10.6 months follow up), most commonly due to P-wave oversensing, which was more frequent in patients implanted early in the study and less frequent among patients implanted later in the study.

"These pivotal data mark the start of a new era in ICD therapy for patients who are at significant risk of dangerously fast heart rhythms," said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "Today's findings are an important clinical milestone toward our goal of delivering a one-system, one-procedure extravascular ICD solution that prevents sudden cardiac arrest while improving the patient experience with a smaller device and moving the lead out of the veins and placing it under the breastbone. The EV ICD system retains the benefits of a completely extravascular system while providing ATP, pause prevention pacing and low defibrillation energy."

The EV ICD Pivotal study is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV ICD system for patients at risk of sudden cardiac death. The EV ICD Pivotal study enrolled 356 patients at 46 sites in 17 countries in North America, Europe, the Middle East, Asia, Australia and New Zealand. Medtronic has received FDA approval for a Continued Access Study while the agency reviews the company's EV ICD pre-market application.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. 

Spotlight

Health providers embrace frictionless business for better access, cost, quality and efficiency. Right service, right channel, right time.

Spotlight

Health providers embrace frictionless business for better access, cost, quality and efficiency. Right service, right channel, right time.

Related News

HEALTH TECHNOLOGY

Pure Health UAE Largest Healthcare Platform Signs a Deal With Equity Group Investments to Invest Half a Billion Dollars in a U.S. Healthcare Company

Pure Health | September 05, 2022

Alpha Dhabi Holding subsidiary, Pure Health, the largest integrated healthcare platform of the United Arab Emirates announced that it has entered into a definitive purchase agreement to acquire a minority equity investment in Ardent Health Services a leading U.S. healthcare provider based in Nashville, Tennessee, for a total investment of $500 million. The investment is subject to customary closing conditions and will be finalized after receipt of all necessary U.S. regulatory approvals. Ardent is the fourth largest privately held acute care hospital operator in the U.S., with 30 hospitals and more than 200 sites of care across six states, and approximately 26,000 employees. Pure Health would achieve a minority equity investment by purchasing an interest in Ardent from Equity Group Investments a Chicago-based private investment firm and majority owner of Ardent. As part of its investment, Pure Health would receive board observer rights but would not have a seat on Ardent’s board of directors. The investment does not include plans for either the expansion of Ardent’s physical footprint or collaboration between Ardent and Pure Health in the delivery of care. Equity Group Investments hosted a signing ceremony, which included Farhan Malik, CEO of Pure Health, Sam Zell, founder and chairman of EGI, and Marty Bonick, president and chief executive officer of Ardent. “One of EGI’s strengths is partnering with like-minded individuals with the experience and passion for how we approach investment opportunities. We look forward to developing a productive relationship with Pure Health as they continue to explore the various dynamics of the U.S. healthcare system,” Sam Zell Commenting on the major investment announcement, Farhan Malik said, “This landmark investment agreement marks a quantum leap for the UAE and the global healthcare industry.” “This is an exciting opportunity for Pure Health, as we continue to build relationships with leading U.S. healthcare providers to leverage the highest standards and best clinical practices to provide an unrivalled healthcare experience for patients in the UAE,” said Malik. “Ardent has a strong track record of delivering outstanding services across the United States, and we look forward to gaining additional knowledge to support our north star of advancing the science of longevity and unlocking time for humanity.” ABOUT PURE HEALTH Pure Health is an integrated healthcare solutions platform with a diversified portfolio of over 25 hospitals and more than 100 clinics offering 200+ specialties covering services from tertiary care to primary care; health insurance that covers over 2.5 million members; group procurement organization; over 150 laboratories; diagnostics services; rehab services; long term care; medical supplies; and health technology services. With more than 50 million annual clinical encounters and over 25,000 employee strength, the company provides healthcare services across the entire continuum of care. Pure Health is committed to enhancing longevity and helping people live longer, happier, and healthier lives. The company’s centers of excellence bring together clinical knowledge, process expertise, technology, and analytics to deliver outcome-focused, world-class quality across all channels of healthcare with a mandate to future-proof the healthcare system for a world of technological singularity. ABOUT EQUITY GROUP INVESTMENTS Equity Group Investments (EGI), founded by Sam Zell more than 50 years ago, has a long track record of building public and private businesses, including the origination and growth of multi-billion-dollar companies. EGI’s flexible capital and open investment mandate enable the firm to pursue opportunistic transactions across industries and geographies, throughout the capital structure, at any point in the economic cycle. EGI’s current portfolio includes investments in transportation and logistics, health care, manufacturing, agribusiness, energy, retail, waste and infrastructure, and real estate. ABOUT ARDENT HEALTH SERVICES Ardent Health Services invests in people, technology and communities. Through its subsidiaries, Ardent owns and operates 30 hospitals and more than 200 sites of care in six states with approximately 26,000 employees, including 1,200+ employed providers. With a focus on evidence-based practices to improve quality care and patient outcomes, four Ardent hospitals were named to Leapfrog’s Top Hospitals in 2021, and eight Ardent hospitals received a Leapfrog Hospital Safety Grade of A for Spring 2022. Based in Nashville, Tennessee, Ardent is owned by current and former members of Ardent’s management team; Equity Group Investments (EGI), a Chicago-based private investment firm; and Ventas, Inc.

Read More

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More

HEALTH TECHNOLOGY

Veranex Expands European MedTech Capabilities With Acquisition of Medidee

Veranex and Medidee Services | September 21, 2022

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland. As a trusted European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for MedTech companies across Europe and the world. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations challenges supports truly full-service MedTech product development and commercialization. “Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage. The combined organization offers offices and expertise across Europe, the U.S., and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.” Veranex CEO David Dockhorn With Medidee’s 11 locations across Europe, India, and Asia-Pacific, and Veranex’s 13 locations across the U.S., Europe, and China, the company now has unprecedented reach to serve clients with a full spectrum of integrated concept-to-commercialization services — design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy, and market access services — all under one umbrella. Medidee is one of the Top 3 medical device consultancy service providers in Europe uniquely positioned as a leader in future key areas such as digital health, machine learning, and cybersecurity. The company also brings expertise in clinical research exclusively focused on medical devices and in vitro diagnostics. “Medidee has a proven track record serving regulatory, clinical, and quality needs for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories across multiple geographies,” shared Medidee co-founders Kim Rochat, Philippe Etter, and Michael Maier. “With these services, coupled with the global infrastructure of Veranex, we expand expertise and resources for the benefit of our clients as well as for all EU innovative manufacturers wishing to access rapidly and efficiently the U.S. market and beyond. We look forward to providing these additional strengths and capabilities,” added the co-founders who take on new roles in the combined organization. About Veranex Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners. About Medidee Services With sites in Switzerland, Germany, Denmark, Belgium, Spain, USA, and APAC, Medidee is a global services supplier serving companies ranging from academic startups to majors. Medidee was established by three partners, all experts in the field of medical devices. With 50 experts in all fields necessary to ensure compliance with the most stringent requirements, Medidee provides the necessary competencies to ensure and demonstrate compliance with all key medical device regulations. Medidee expends regularly to provide the best resources and competencies and supports more than 350 manufactures all over the world.

Read More